Exhibit 16.1
Deloitte &Touche LLP | |
1Concorde Gate | |
Suite 200 | |
Toronto, ON M3C 4G4 | |
Canada | |
|
|
| Tel: 416-601-6150 |
| Fax: 416-601-6610 |
| www.deloitte.ca |
July 16,2009
Ontario Securities Commission | and to |
British Columbia Securities Commission | McGovem, Hurley, Cunningham, LLP |
Alberta Securities Commission | Chartered Accountants |
Securities Exchange Commission |
|
Dear Sirs/Mesdames:
Subject:
Stellar Pharmaceuticals Inc.
Notice of Change of Auditor
In compliance with National Instrument 51-102 -Continuous Disclosure Obligations, and Item 4.01 - Change of Registrant's Certifying Accountant, please be advised that we have read the Notice of Change of Auditor prepared by Stellar Pharmaceuticals Inc. dated May 19, 2009 and revised on July 13, 2009, and we agree with the contents of the said Notice.
Yours truly,
Chartered Accountants
Licensed Public Accountants
cc: Board of Directors
Member de/Member of Deloitte Touche Tohmatru